The prevalence of allergic rhinitis (AR) is increasing at an alarming rate throughout the world.  India has an estimated number of 15-20 million patients with allergic bronchial asthma and 30-80% of these suffer from AR. So, AR is considered as a major chronic respiratory disease due to its prevalence, impact on quality of life (QoL), work/school performance and productivity, economic burden and links with asthma. This research aims at testing the role of classical homeopathy in bringing changes in serum immunoglobulin E (IgE) level and absolute eosinophil count (primary outcome measures) and QoL issues related to AR (secondary outcome measures) by comparing the pre-trial and post-trial data. An open label, single arm, experimental, prospective, non-randomized, non-controlled, before and after comparison pilot study was carried on thirty participants suffering from chronic AR. Institutional ethical clearance was obtained; then thirty four consenting patients were enrolled after screening by eligibility criteria and were allocated to classical homeopathic treatment. Four cases were dropped out and thirty cases were regular. Outcome measures were assessed and analyzed after one year. After one year of homeopathic treatment, lowering of serum IgE level (1006.83±395.17 vs 336.5±126.96; P = 0.00003), absolute eosinophil count of blood (600.33±103.61 vs 302.5±82.21; P = 0.00008) and QoL scores of AR (113.67±17.85 vs 58.13±12.39; P = 0.00006) were statistically significant. No adverse effects and/or complications were observed. Data suggest that classical homeopathic treatment may be a useful measure for the patients suffering from chronic AR. However, multi-centric randomized controlled trials with larger sample size and longer duration should be undertaken for confirmation of the conclusion.